Background We conducted a retrospective, questionnaire-based analysis to assess the outcomes of advanced renal cell carcinoma (RCC) in Japanese patients treated with sorafenib in the daily clinical setting. Patients and methods Patients (n = 110) were treated with sorafenib 400 mg twice daily at 12 centers. Overall survival (OS), progression-free survival (PFS), safety, and prognostic factors associated with PFS were assessed. Results The median OS was not reached within the study period, while the median PFS was 11.0 mo [95 % confidence interval (CI), 6.6 to 14.4 mo]. Univariate analysis showed that higher C-reactive protein (CRP) level, lower Na ? level, and presence of liver metastasis were significant predictors of poorer PFS (p \ 0.05, respectively). Among these variables, multivariate analysis identified higher CRP level (p = 0.004) and the presence of liver metastasis (p \ 0.001) as being significantly associated with poorer PFS. The most common adverse event was skin toxicity (67 %), followed by gastrointestinal symptoms (26 %), hypertension (22 %), fatigue (19 %), hematological toxicity (10 %), and hemorrhage (6 %). The incidence of adverse events was comparable to that of previously reported clinical trials.
Introduction
Tyrosine kinase inhibitors (TKIs) are a standard therapeutic option for metastatic renal cell carcinoma (RCC). Sorafenib is an oral tablet that inhibits tyrosine kinase receptor, such as VEGFR-2, VEGFR-3, Raf, PDGFR-b, Flt-3, and c-Kit, that are associated with tumor cell proliferation and angiogenesis [1] [2] [3] . This inhibitor was found to be an effective treatment for unresectable or metastatic RCC in clinical trials conducted in Japan and elsewhere [4] . Sorafenib became available on the Japanese market in April 2008, and it has been widely used to treat advanced RCC.
Recent findings of the phase II trial of its efficacy and safety in Japanese patients with advanced RCC showed that long-term use of sorafenib after cytokine therapy is well tolerated and prolongs survival [5] . However, the patient population in the phase II trial included only patients in which cytokine therapy failed; therefore the results cannot be safely generalized to include daily clinical practice. Sorafenib is currently used as a first-line therapy in addition to a second-line therapy after cytokine or other TKI treatments. Thus, confirming the effectiveness of sorafenib in daily clinical practice is essential. To investigate the efficacy and safety of sorafenib for Japanese patients with advanced RCC in daily clinical practice, we retrospectively analyzed the available data on such patients at 12 centers in Nagano and Yamanashi prefectures, Japan.
Patients and methods

Patients and study design
This multicenter, retrospective analysis of sorafenib was conducted at 12 centers in Nagano and Yamanashi prefectures, Japan (see the ''Appendix''), and was approved by the ethics committee of Shinshu University School of Medicine. A total of 110 Japanese patients with advanced RCC treated with sorafenib were included. Follow-up started on the first administration of sorafenib, and it ended on August 1, 2012 or upon the withdrawal or death of the patient. Administration of sorafenib was based on the procedure approved by the Ministry of Health, Labour and Welfare of Japan. Patients received oral sorafenib (Nexavar Ò ; Bayer HealthCare, Osaka, Japan) 400 mg twice daily on a continuous basis, and an increase in dosage was not permitted. Administration of sorafenib was discontinued if the patient had progressive disease, further sorafenib therapy was unlikely to be beneficial, or sorafenib therapy was not tolerated by the patient. For those patients, other drugs such as sunitinib, everolimus, or temsirolimus were used in the treatment.
Patient clinical data were collected through a questionnaire that included the following information: patient background information, histological information, treatment history of TKIs, and outcome. Patient background information included gender, age, date of diagnosis, medical history, history of previous use of cytokines or TKIs, Memorial Sloan-Kettering Cancer Center (MSKCC) risk criteria, Karnofsky performance status (KPS), as well as the results of hematologic tests. Information on the treatment history with TKIs included duration of therapy, dose intensity, and outcome. The questionnaires were sent to all 12 centers on July 31, 2012. Results from the questionnaires that were returned by September 30, 2012 are presented herein.
Outcomes
The primary endpoint of the present study was overall survival (OS), and the secondary endpoints were progression-free survival (PFS) and safety. For safety, information on adverse events from the following categories were collected: (1) skin toxicity, including hand-foot syndrome; (2) hematological toxicity, including abnormal changes in white blood cell count, platelet count, or hemoglobin level; (3) hypertension; (4) hemorrhage; (5) gastrointestinal symptoms; and (6) fatigue.
Statistical analysis
Patient background information was summarized in a descriptive manner. The median OS and PFS were estimated using the Kaplan-Meier method and the log-rank test was used to compare survival curves. To evaluate the factors that are prognostic for survival, univariate and multivariate Cox regression analyses were performed. P values of \0.05 were considered to indicate statistically significant differences. 
Results
Patient backgrounds
There were 83 men and 27 women with a median age of 67 years (range 31-84 years, Table 1 ). Eighty-one patients (73.6 %) had clear cell carcinoma and 100 patients (91.0 %) were in stage IV. Based on the MSKCC risk classification, the majority of the patients were classified as favorable (34.5 %) and intermediate (58.2 %). Only 8 patients (7.3 %) were classified as having poor risk. Fortyfour patients (40.0 %) were treated with a TKI as a firstline therapy. Among them, 40 patients (91.0 %) received sorafenib. During the study period, more than half of the patients (56.4 %) were able to continue sorafenib therapy without dose reduction. The median duration of sorafenib therapy was 470 days (range 35-1631 days). The most common metastatic sites (Table 2) were lung (65.5 %), lymph node (35.5 %), bone (19.1 %), and liver (11.8 %). Figure 1 shows the treatment histories of the patients (i.e., how many had a previous nephrectomy, previous cytokine therapy, and sorafenib as a first-or second-line treatment).
Overall survival
The median OS was not reached within the study period in any of the 110 patients, and the 1-year survival rate was 77.5 % [95 % confidence interval (CI), 67.8-84.6 %] (Fig. 2a) . The median OS was not reached for patients with normal C-reactive protein (CRP) levels or for patients with no liver metastasis. For patients with higher CRP levels, the median OS was 18.0 mo (95 % CI, 11.4 to not applicable: NA, p = 0.034) and 18.6 mo (95 % CI, 3.3 to NA, p = 0.005) for patients with liver metastasis. Moreover, the median OS for patients with favorable risk, based on the MSKCC risk classification, was not reached. This was significantly higher than the OS of 22.5 mo (95 % CI, 14.3 to NA) for patients with intermediate and poor risk (p = 0.025) based on the MSKCC risk classification (Fig. 2b) . There was also a significantly higher OS (95 %CI, 39.8 to NA) for patients who received cytokine therapy before sorafenib (n = 62) than for those who did not receive cytokine therapy (n = 37) (Figs. 1, 2c , p = 0.002), and a significantly higher OS (95 % CI, NA to NA) for nephrectomy patients who received cytokine therapy before sorafenib (n = 55) than for those who did not receive cytokine therapy (n = 24) (Figs. 1, 2d , p = 0.034). However, there was no significant difference in OS (95 % CI, NA to NA) between patients with clear cell carcinoma (n = 81) and those with non-clear cell carcinoma (n = 10) before sorafenib (Figs. 1, 2e , p = 0.487).
Progression-free survival
Among all 110 patients, the median PFS was 11.0 mo (95 % CI, 6.6-14.4; Fig. 3a) . The median PFS was 11.0 mo (95 % CI, 6.6-16.8) for patients who had KPS C 80 % and 3.5 mo (95 % CI, 1.5 to NA) for patients who had KPS \ 80 % (p = 0.022). For patients with liver metastasis, the median PFS was 3.1 mo (95 % CI, 1.6-5.5), and it was 12.3 mo (95 % CI, 7.5-20.1) without liver metastasis (p \ 0.001). For patients with lymph node metastasis (39 out of 110, Table 2), the (Fig. 3b) . There was also a significantly higher PFS of 17.1 mo (95 % CI, 6.9-29.3) for patients who received cytokine therapy before sorafenib (n = 62) than for those who did not receive cytokine therapy (n = 37) (Figs. 1, 3c , p = 0.017). However, there was no significant difference in PFS between nephrectomy patients who received cytokine therapy (n = 55) and those who did not receive cytokine therapy (n = 24) before sorafenib (Figs. 1, 3d, Fig. 2a -e Probability estimates of overall survival (OS). a The 1-year survival rate for patients (n = 110) treated with sorafenib was 77.5 %, and the median OS was not reached by the study population. b For patients classified as having favorable (F) risk according to the Memorial Sloan-Kettering Cancer Center (MSKCC) classification, the 1-year survival rate was 88.5 %, and the median OS was not reached. For patients classified as having intermediate or poor (IP) risk, the 1-year survival rate was 71.2 %, and the median OS was 22.5 mo. c For patients who had cytokine therapy before sorafenib regardless of whether they had a nephrectomy, the 1-year survival rate was 84.0 % and the median OS was not reached. For patients who had cytokine therapy before sorafenib regardless of whether they had a nephrectomy, the 1-year survival rate was 63.9 % and the median OS was 21.0 mo. d For patients who had cytokine therapy before sorafenib with nephrectomy, the 1-year survival rate was 83.9 % and the median OS was not reached. For patients who had cytokine therapy before sorafenib with nephrectomy, the 1-year survival rate was 72.8 % and the median OS was 30.4 mo. e For patients with clear cell carcinoma, the 1-year survival rate was 82.9 % and the median OS was not reached. For patients with non-clear cell carcinoma, the 1-year survival rate was 64 % and the median OS was not reached for patients with clear cell carcinoma (n = 81) than for those with non-clear cell carcinoma (n = 10) (Figs. 1, 3e , p \ 0.001).
Univariate and multivariate analysis
Univariate analysis showed that a higher CRP level, a lower Na ? level, and the presence of liver metastasis were significant predictors of poorer PFS (p \ 0.05, respectively). Among these variables, multivariate analysis identified a higher CRP level (p = 0.004) and the presence of liver metastasis (p \ 0.001) as being significantly associated with poorer PFS (Table 3) .
Adverse events
We analyzed the adverse events that occurred in the 110 cases. The most common adverse event was skin toxicity (67 %). Other adverse events were gastrointestinal symptoms (26 %), hypertension (22 % Fig. 3a -e Probability estimates for progression-free survival (PFS). a The median 1-year PFS rate for patients (n = 110) treated with sorafenib was 46.3 %, and the median PFS was 11.0 mo. b For patients classified as having favorable (F) risk according to the Memorial Sloan-Kettering Cancer Center (MSKCC) classification, the 1-year PFS rate was 57.8 % and the median PFS was 14.3 mo. For patients classified as having intermediate or poor (IP) risk, the 1-year PFS rate was 39.5 % and the median PFS was 7.5 mo. c For patients who had cytokine therapy before sorafenib regardless of whether they had a nephrectomy, the 1-year survival rate was 60.0 % and the median PFS was 17.1 mo. For patients who did not receive cytokine therapy before sorafenib regardless of whether they had a nephrectomy, the 1-year survival rate was 24.9 % and the median PFS was 7.53 mo. d For patients who received cytokine therapy before sorafenib with nephrectomy, the 1-year survival rate was 57.9 % and the median PFS was 20.1 mo. For patients who did not receive cytokine therapy before sorafenib with nephrectomy, the 1-year survival rate was 26.2 % and the median PFS was 7.77 mo. e For patients with clear cell carcinoma, the 1-year survival rate was 49.1 % and the median PFS was 12.1 mo. For patients with non-clear cell carcinoma, the 1-year survival rate was 15.2 % and the median PFS was 2.93 mo hematological toxicity (10 %), and hemorrhage (6 %). Grade 3 side events were skin toxicity (5 cases), gastrointestinal symptom (diarrhea, pancreatitis; 4 cases), severe general fatigue (5 cases), thrombocytopenia (1 case), heart failure (1 case), interstitial pneumonia (1 case), and lung bleeding (1 case). All events were recovered by stopping sorafenib.
Discussion
In the present study, the clinical data of 110 Japanese patients with advanced RCC treated with sorafenib in the daily clinical setting were retrospectively analyzed. Sorafenib became available on the market in Japan later than in Western countries, and thus there is less evidence for the efficacy and safety of sorafenib therapy for advanced RCC in Japanese patients. Therefore, it is important to analyze data obtained in the daily clinical setting. In addition, it is essential to determine the prognostic factors that are associated with sorafenib therapy. Post-marketing surveillance of sorafenib for advanced RCC in Japan is now complete, and final data are available [6] . According to data from 3,171 patients, the median PFS is 7.3 mo (95 % CI, 6.8-8.2 mo) and the 1-year survival rate is 75.4 % (95 % CI, 73.5-77.1 %). The final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study showed that the median PFS was 6.6 mo [7] , and the final results of the North American Advanced Renal Cell Carcinoma Sorafenib (NA-ARCCS) expanded-access study showed that the median PFS was 9.0 mo [8] . Although there were differences in patient background and study protocols between the present study and the other studies described above, the efficacy of sorafenib in the present study was not much different to its efficacy in those other studies.
Efficacy data from pre-marketing phase II/III studies showed that the median OS and PFS were 25.3 and 7.9 mo, respectively, in a Japanese phase II study [5] , and 17.8 and 5.5 mo in the Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) study [3, 9] . Compared to those results, the present data indicated better survival. Before sorafenib became available in Japan, the median OS of Japanese patients with metastatic RCC treated with cytokine therapy was 24.9 mo [10] . Although we cannot directly compare the results of different studies, sorafenib therapy could be comparable to or more effective than cytokine therapy for patients with advanced RCC. In this study, although the cytokine-pretreated group may contain patients at lower risk than the patients in the non-pretreated group, cytokine pretreatment may have contributed to the good OS and PFS presented by this group.
In our multivariate analysis, two factors-higher CRP levels and presence of liver metastasis-were significantly associated with a short PFS. Systemic inflammation is associated with cancer progression, and factors that are associated with inflammation have been considered potential biomarkers [11, 12] . CRP is an acute-phase reactant protein that is exclusively synthesized by hepatocytes. The serum concentration of CRP rises as much as 1000-fold in immediate response to the release of cytokines or chemical mediators during various pathological conditions, including acute inflammation, infection, tissue or cell necrosis, and some malignancies (including RCC). Previously reported studies indicated that higher CRP levels are significantly associated with poor OS in patients with advanced RCC [11] [12] [13] [14] [15] [16] . Thus, CRP can be used as an indicator of patient outcome, and monitoring CRP levels might help to predict the course of the disease.
Metastasis of RCC to the liver is widely known to be one of the major factors in poor outcome. Although sorafenib therapy is likely to be more effective than conventional cytokine therapy, liver metastasis still affects prognosis. On the other hand, the efficacy of sorafenib in patients who had lung, lymph node, and bone metastasis was similar to its efficacy in those who did not. These results suggest that sorafenib may be beneficial to the overall outcomes for RCC patients with metastasis other than to the liver.
The incidence rate of adverse events reported in the present study was expected and is comparable to those seen in previously reported clinical studies [5, [7] [8] [9] . However, information on the grading of adverse events in the present study was absent.
In the present work, we have reported essential clinical data relating to the daily use of sorafenib for the treatment of advanced RCC. However, there were some limitations of our study. The clinical data were collected by questionnaire and analyzed retrospectively. Due to the small number of samples and the study design used, the results are not directly comparable to those from large-scale randomized controlled studies. The safety data were limited to the following six categories: skin toxicity including handfoot syndrome, hematological toxicity, hypertension, hemorrhage, gastrointestinal symptoms, and fatigue, which are known to be common adverse events of sorafenib therapy. We were unable to collect data on other adverse events that may be clinically important but occur at a low incidence. In summary, the present retrospective study showed additional clinical information on sorafenib therapy for the treatment of advanced RCC in the daily clinical setting. The survival of the patients in the present study was better than that previously reported, while the safety of sorafenib therapy was comparable. In addition, multivariate analysis indicated that higher CRP levels and the presence of liver metastasis were significantly associated with short PFS.
